<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126357</url>
  </required_header>
  <id_info>
    <org_study_id>CSD170401</org_study_id>
    <nct_id>NCT03126357</nct_id>
  </id_info>
  <brief_title>CSD170401: Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement</brief_title>
  <official_title>CSD170401: A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine elements of abuse liability (AL) related to potential product&#xD;
      adoption of three electronic tobacco vapor products by current smokers relative to high and&#xD;
      low AL comparator products (usual brand cigarette and nicotine gum, respectively). Changes in&#xD;
      subjective measures, speed and amount of nicotine uptake, and maximum changes in&#xD;
      physiological effects during and after product use that follows a 12-hour (minimum) tobacco&#xD;
      and nicotine abstinence period, will be determined. The electronic tobacco vapor products&#xD;
      will not be compared to each other.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, open-label, crossover study, designed to evaluate&#xD;
      subjective effects (i.e., Product Liking [PL], Overall Intent to Use Again [OIUA], Product&#xD;
      Effects [PE], Urge to Smoke [UTS], and Overall Product Liking [OPL]), plasma nicotine uptake,&#xD;
      and physiological measures (blood pressure and heart rate) during and following ad libitum&#xD;
      use of the following five IPs by healthy subjects. Subjects will be evaluated in five&#xD;
      separate Test Sessions and the active period of each Test Session will last for approximately&#xD;
      4 hours during and following IP use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">May 25, 2017</completion_date>
  <primary_completion_date type="Actual">May 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUECPL 15-240</measure>
    <time_frame>-5, 5, 15, 30, 45, 60, 90, 120, 150, 180, and 240 Minutes</time_frame>
    <description>Area under the product liking (PL) NRS score-versus-time curve from 15 minutes to 240 minutes after the start of investigational product (IP) use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax PL</measure>
    <time_frame>-5, 5, 15, 30, 45, 60, 90, 120, 150, 180, and 240 Minutes</time_frame>
    <description>Maximum response for product effects with regards to PL score after the start of IP use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eoverall IUA</measure>
    <time_frame>240 Minutes</time_frame>
    <description>Overall intent to use again (IUA), measured at 240 minutes after the start of IP use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCnic 0-240</measure>
    <time_frame>-5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, and 240 Minutes.</time_frame>
    <description>Baseline-adjusted area under the nicotine concentration-versus-time curve from time zero to 240 minutes after the start of IP use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, and 240 Minutes.</time_frame>
    <description>Maximum baseline-adjusted plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>-5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, and 240 Minutes.</time_frame>
    <description>Time to maximum baseline-adjusted plasma concentration.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>Usual Brand Cigarette</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>FT21039 an electronic tobacco vapor product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>FT21092 an electronic tobacco vapor product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>FT21018 an electronic tobacco vapor product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>4mg nicotine gum</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Able to safely perform the required study procedures, as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          4. Expired breath carbon monoxide level is ≥ 15 ppm and ≤ 100 ppm at Screening and Day 1.&#xD;
&#xD;
          5. Smokes only combustible, filtered, non-menthol cigarettes, 83 mm to 100 mm in length.&#xD;
&#xD;
          6. Agrees to smoke same usual brand (UB) cigarette throughout the study period. Usual&#xD;
             brand cigarette is defined as the cigarette brand style currently smoked most&#xD;
             frequently by the subject.&#xD;
&#xD;
          7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least&#xD;
             6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt&#xD;
             (prior to 30 days of Screening), or clinical study participation (prior to 30 days of&#xD;
             Screening) will be allowed at the discretion of the Investigator.&#xD;
&#xD;
          8. Response at Screening to Fagerström Test for Cigarette Dependence (FTCD) Question 1&#xD;
             (&quot;How soon after you wake up do you smoke your first cigarette?&quot;) is either &quot;Within 5&#xD;
             minutes&quot; or &quot;6-30 minutes.&quot;&#xD;
&#xD;
          9. Willing to use UB cigarette, electronic tobacco vapor products, and Nicorette gum&#xD;
             during the study period.&#xD;
&#xD;
         10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each&#xD;
             Test Session.&#xD;
&#xD;
         11. Females of childbearing potential must be willing to use a form of contraception&#xD;
             acceptable to the Investigator from the time of signing informed consent until study&#xD;
             discharge. Examples of acceptable forms of contraception include, but are not limited&#xD;
             to, the following.&#xD;
&#xD;
               1. Surgeries:&#xD;
&#xD;
                    -  Hysterectomy at least 6 months prior to randomization&#xD;
&#xD;
                    -  Oophorectomy at least 6 months prior to randomization&#xD;
&#xD;
                    -  Tubal ligation at least 6 months prior to randomization&#xD;
&#xD;
               2. Transcervical sterilization at least 6 months prior to randomization&#xD;
&#xD;
               3. Hormonal birth control at least 3 months prior to randomization&#xD;
&#xD;
               4. Non-hormonal intrauterine device at least 3 months prior to randomization&#xD;
&#xD;
               5. Double barrier methods (e.g., condom and spermicide) at least 14 days prior to&#xD;
                  randomization&#xD;
&#xD;
               6. Abstinence at least 14 days prior to randomization&#xD;
&#xD;
               7. Vasectomized partner is acceptable birth control for females provided the surgery&#xD;
                  was performed at least 6 months prior to randomization&#xD;
&#xD;
               8. Postmenopausal at least 1 year prior to randomization and have&#xD;
                  follicle-stimulating hormone (FSH) levels consistent with postmenopausal status&#xD;
                  at screening as per Investigator or designee judgment&#xD;
&#xD;
         12. Agrees to in-clinic confinement of 11 days and 10 nights.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant or unstable/uncontrolled acute or chronic medical&#xD;
             conditions at Screening or Day 1, as determined by the Investigator, that would&#xD;
             preclude the subject from participating safely in the study (e.g., uncontrolled&#xD;
             hypertension, lung disease, cardiac disease, neurological disease or psychiatric&#xD;
             disorders) based on safety assessments such as clinical laboratory tests, medical&#xD;
             history, and physical/oral examinations.&#xD;
&#xD;
          2. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          3. History or presence of stomach ulcers.&#xD;
&#xD;
          4. At risk for heart disease that would preclude the subject from participating safely in&#xD;
             the study, as determined by the Investigator.&#xD;
&#xD;
          5. Use of medicine for the treatment of depression, unless on a stable dose for the past&#xD;
             6 months prior to screening and deemed clinically stable by the PI.&#xD;
&#xD;
          6. Current scheduled treatment for asthma within the past consecutive 12 months prior to&#xD;
             screening. As needed treatment, such as inhalers, may be included at the PIs&#xD;
             discretion pending approval from the medical monitor.&#xD;
&#xD;
          7. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          8. Systolic blood pressure of &gt; 160 mmHg or diastolic blood pressure of &gt; 95 mmHg at&#xD;
             Screening, measured after being seated for at least 5 minutes.&#xD;
&#xD;
          9. Hemoglobin level is &lt; 12 g/dL at Screening.&#xD;
&#xD;
         10. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         11. History or presence of hemophilia or any other bleeding disorders.&#xD;
&#xD;
         12. History or presence of clotting disorders and/or use of anticoagulants (e.g.,&#xD;
             clopidogrel [Plavix®], warfarin [Coumadin®, Jantoven®] and aspirin [&gt; 325 mg/day], see&#xD;
             Section 7.4 &quot;Concomitant Medications&quot;).&#xD;
&#xD;
         13. Whole blood donation within 8 weeks (≤ 56 days) prior to Screening.&#xD;
&#xD;
         14. Plasma donation within (≤) 7 days prior to Screening.&#xD;
&#xD;
         15. Body mass index &lt; 18.5 or &gt; 40.0 kg/m2 at Screening.&#xD;
&#xD;
         16. Weight of ≤ 110 pounds at Screening.&#xD;
&#xD;
         17. Poor peripheral venous access.&#xD;
&#xD;
         18. Postponing a decision to quit smoking (defined as planning a quit attempt within [≤]&#xD;
             30 days of Screening) to participate in this study or previous attempt within (≤) 30&#xD;
             days prior to Screening.&#xD;
&#xD;
         19. Employed by a tobacco company, the study site, or handles unprocessed tobacco as part&#xD;
             of his or her job.&#xD;
&#xD;
         20. Use of any medication or supplement that aids smoking cessation, including but not&#xD;
             limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge,&#xD;
             patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract&#xD;
             within (≤) 30 days prior to Screening.&#xD;
&#xD;
         21. Use of an electronic tobacco vapor product or other tobacco or nicotine-containing&#xD;
             product (e.g., lozenges, moist snuff) within (≤) 30 days prior to Screening.&#xD;
&#xD;
         22. Drinks more than 14 servings of alcoholic beverages per week (one serving = 12 oz of&#xD;
             beer, 6 oz of wine, or 1.5 oz of liquor).&#xD;
&#xD;
         23. Females who have a positive pregnancy test, are pregnant, breastfeeding, or who intend&#xD;
             to become pregnant during the course of the study.&#xD;
&#xD;
         24. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         25. A positive urine drug screen without disclosure of corresponding prescribed&#xD;
             concomitant medication(s), at Screening or Day 1.&#xD;
&#xD;
         26. A positive alcohol result at Screening or Day 1.&#xD;
&#xD;
         27. Determined by the Investigator to be inappropriate for this study, including a subject&#xD;
             who is unable to communicate or unwilling to cooperate with the study staff.&#xD;
&#xD;
         28. Participation in another clinical trial within (≤) 30 days prior to Screening. The&#xD;
             30-day window for each subject will be derived from the date of the last study event&#xD;
             in the previous study to Screening of the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Tomek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

